Annovis Bio files provisional patent for manufacturing process of buntanetap

Annovis Bio announced the filing of a provisional patent covering the manufacturing process of new solid forms of buntanetap. This patent encompasses the methods for manufacturing the new crystalline form of buntanetap, which has demonstrated exceptional stability and efficacy. The patent also covers the entire synthesis process, from basic starting materials to finished GMP product, suitable for manufacturing scale at ton quantities. The new process offers significant benefits, including excellent yields, the avoidance of potentially genotoxic reagents, and a purer product. The CMC protocol was submitted to the FDA and will be discussed in July, with the goal of continuing development of our drug and filing the NDA with the new crystal form.